Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
Status:
Terminated
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
To define the relative efficacy, safety and tolerability profiles of oral daily MBX-102 at
daily doses of 400 and 600 mg vs. placebo and Actos® 30 mg (up-titrated to 45 mg after 8
weeks) when administered for up to 24 weeks in patients inadequately controlled with a stable
dose of metformin (≥ 1500 mg/day).